Methods for treating dental conditions using tissue scaffolds
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61C-005/04
A61B-019/02
A61B-019/00
출원번호
US-0684226
(2003-10-10)
등록번호
US-7309232
(2007-12-18)
발명자
/ 주소
Rutherford,Bruce
Somogyi,Christopher
White,Clinton
Rabins,Erick
출원인 / 주소
Dentigenix Inc.
대리인 / 주소
Nixon Peabody LLP
인용정보
피인용 횟수 :
46인용 특허 :
107
초록▼
The invention provides methods, apparatus and kits for regenerating dental tissue in vivo that are useful for treating a variety of dental conditions, exemplified by treatment of caries. The invention uses tissue scaffold wafers, preferably made of PGA, PLLA, PDLLA or PLGA dimensioned to fit into a
The invention provides methods, apparatus and kits for regenerating dental tissue in vivo that are useful for treating a variety of dental conditions, exemplified by treatment of caries. The invention uses tissue scaffold wafers, preferably made of PGA, PLLA, PDLLA or PLGA dimensioned to fit into a hole of corresponding sized drilled into the tooth of subject to expose dental pulp in vivo. In certain embodiments the tissue scaffold wafer further comprises calcium phosphate and fluoride. The tissue scaffold wafer may be secured into the hole with a hydrogel, a cement or other suitable material. Either the wafer or the hydrogel or both contain a morphogenic agent, such as a member encoded by the TGF-β supergene family, that promotes regeneration and differentiation of healthy dental tissue in vivo, which in turn leads to remineralization of dentin and enamel. The tissue scaffold may further include an antibiotic or anti-inflammatory agent.
대표청구항▼
The invention claimed is: 1. A method for treating a subject's tooth that needs regeneration of dentin, comprising, forming a hole in the tooth of the subject in vivo, the hole being of a depth sufficient to expose at least a portion of pulp; inserting a tissue scaffold into the hole so that a port
The invention claimed is: 1. A method for treating a subject's tooth that needs regeneration of dentin, comprising, forming a hole in the tooth of the subject in vivo, the hole being of a depth sufficient to expose at least a portion of pulp; inserting a tissue scaffold into the hole so that a portion of the tissue scaffold contacts at least a portion of the exposed pulp; and regenerating dentin by allowing sufficient time for tissue to grow in vivo, from the pulp into the tissue scaffold, wherein that the tissue scaffold inserted into the hole does not include ex vivo cultured tissue. 2. The method of claim 1 wherein the tissue scaffold is formed into a shape dimensioned to fit snuggly into the hole that is formed so that the tissue scaffold does not move more than 0.1 mm in a lateral direction in the hole. 3. The method of claim 1 wherein the tissue scaffold is formed into a cylindrical wafer having a diameter of about 2 to about 5 mm and a height of about 0.1 to about 0.5 mm. 4. The method of claim 1 further comprising inserting dental stem cells into the hole between the exposed portion of the pulp and the tissue scaffold. 5. The method of claim 1 wherein the tissue scaffold is seeded with dental pulp stem cells prior to insertion into the hole. 6. The method of claim 1 wherein the tissue scaffold is comprised of calcium phosphate associated therewith. 7. The method of claim 6 wherein the tissue scaffold is comprised of fluoride associated therewith. 8. The method of claim 1 wherein the tissue scaffold is comprised of scaffolding material selected from the group consisting of PLLA, PDLLA, PGA and PLGA. 9. The method of claim 1 wherein the tissue scaffold comprised of scaffolding material is PLGA. 10. The method of claim 1 wherein the tissue scaffold is farther comprised of a physiologically effective amount of a morphogenic agent that promotes growth of dentin tissue. 11. The method of claim 10 wherein the morphogenic agent is encoded by a member of the TGF-β supergene family. 12. The method of claim 10 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, VEGF, FGF-1, FGF-2, IGF-1, IGF-2, PDGF, GDF-1, GDF-2, GDF-3, GDF-4, and GDF-5. 13. The method of claim 10 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, and GDF-5. 14. The method of claim 1 wherein the tissue scaffold is further comprised of an active agent selected from the group consisting of an anti-bacterial agent and an anti-inflammatory agent. 15. The method of claim 1 wherein the tissue scaffold has the shape of a cylindrical wafer having an upper surface, a downwardly extending cylindrical side, and a lower surface. 16. The method of claim 1 further including applying a barrier layer in contact with an exposed surface of the scaffold material to seal the scaffold material in the hole. 17. The method of claim 16 wherein the barrier layer is comprised of a hydrogel. 18. The method of claim 17 wherein the hydrogel comprises a physiologically effective amount of a morphogenic agent that promotes growth of dentin tissue. 19. The method of claim 17 wherein the barrier hydrogel comprises an active agent selected from the group consisting of an anti-bacterial agent and an anti-inflammatory agent. 20. The method of claim 17 wherein the morphogenic agent is encoded by a member of the TGF-β supergene family. 21. The method of claim 17 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, VEGF, FGF-1, FGF-2, IGF-1, IGF-2, PDGF, GDF-1, GDF-2, GDF-3, GDF-4, and GDF-5. 22. The method of claim 17 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, and GDF-5. 23. The method of claim 1 further including covering the hole with a cement or amalgam that contacts at least a portion of tooth enamel. 24. The method of claim 23 wherein the cement is comprised of di-calcium phosphate and tetra calcium phosphate. 25. The method of claim 23 wherein the cement is comprised of calcium phosphate and fluoride. 26. The method of claim 1 wherein the subject has asymptomatic caries and the act of forming the hole exposes a portion of the pulp located in the coronal pulp chamber. 27. The method of claim 1 wherein the subject has need of a root canal and the act forming the holes exposes a portion of the pulp between at least one of the coronal pulp chamber and the root canal. 28. A device for treating a tooth comprising, a tissue scaffold comprised of a scaffolding polymer configured as a wafer that fits snuggly into a corresponding hole that is formed in a tooth of the subject so that the tissue scaffold does not move more than 0.1 mm in a lateral direction in the hole, wherein the tissue scaffold does not include ex vivo cultured tissue. 29. The device of claim 28 wherein the hole of corresponding size is formed by an act of drilling the tooth. 30. The device of claim 28 wherein the wafer is cylindrical and has a diameter of about 2 to about 5 mm and a has height of about 2 to about 4 mm. 31. The device of claim 28 wherein the scaffolding polymer is made of a material selected from the group consisting of PLLA, PDLLA, PGA and PLGA. 32. The device of claim 28 wherein the scaffolding material is associated with calcium phosphate. 33. The device of claim 32 wherein the wafer is further associated with fluoride. 34. The device of claim 28 further comprising a pharmaceutically acceptable hydrating liquid. 35. The device of claim 28 wherein the wafer has a top surface, a bottom surface and a side perimeter surface between the top and bottom surfaces, and wherein at least one of the top and bottom surfaces are marked with a pattern that alters appearance when the wafer is crushed. 36. The device of claim 35 wherein the pattern is comprised of set of concentric circles. 37. The device of claim 35 wherein the pattern is comprised of a dye that alters color when the wafer is compressed. 38. A kit containing a plurality of wafers according to claim 28 and wherein the plurality of wafers are of a plurality of sizes selected to correspond with a plurality of hole sizes. 39. The kit of claim 38 wherein the plurality of hole sizes correspond to a plurality of holes made by drilling a tooth with any one of a plurality of dental drill bit sizes. 40. A kit for providing a method of treating dental conditions, comprising: a dry tissue scaffold wafer dimensioned to be received into a hole of corresponding size formed in a tooth of a subject; a well configured to hold the tissue scaffold wafer in a dry state, a second well adjacent to the first well, the second well holding a hydrating liquid comprising a pharmaceutically acceptable liquid; and a breakable partition separating the first and second wells, the breakable partition being structured to break by a force applied by a human hand causing the tissue scaffold wafer to contact hydrating liquid when the breakable partition is broken. 41. The kit of claim 40 wherein a plurality of the first wells are configured with a plurality of second wells, each member of the plurality of first and second wells having the breakable partition between the wells. 42. The kit of claim 41 wherein the plurality of first wells is dimensioned to hold a plurality of dry wafers of different sizes. 43. The kit of claim 40, further comprising a hydrogel material. 44. The kit of claim 43 wherein the hydrogel is hydrated, contained in a well in the kit, and has a size that corresponds to a size of the tissue scaffold wafer. 45. The kit of claim 44 including a plurality of hydrogels. 46. The kit of claim 43 wherein the hydrogel material is provided in a dry state in the kit. 47. The kit of claim 46 further comprising a hydrating liquid for hydrating the dry hydrogel material. 48. The kit of claim 46 wherein at least one of the dry tissue scaffold or the hydrating agent or a hydrogel optionally included with the kit, contains a morphogenic agent. 49. The kit of claim 48 wherein the morphogenic agent is encoded by a member of the TGF-β supergene family. 50. The kit of claim 48 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, VEGF, FGF-1, FGF-2, IGF-1, IGF-2, PDGF, GDF-1, GDF-2, GDF-3, GDF-4, and GDF-5. 51. The kit of claim 48 wherein the morphogenic agent is selected from the group consisting of BMP-2, BMP 4, BMP-7, and GDF-5. 52. The kit of claim 48 wherein the morphogenic agent is supplied with the hydrating liquid. 53. The kit of claim 48 wherein the morphogenic agent is supplied with the hydrogel. 54. The kit of claim 48 wherein the morphogenic agent is supplied with the dry tissue scaffold water. 55. A device for supporting a tissue scaffold wafer comprising, a support casing at least partially surrounding the tissue scaffold wafer, the tissue scaffold wafer being made of a porous scaffolding material having a first crushing resistance and the support casing being made of a material having a second crushing resistance greater than the first crushing resistance. 56. The device of claim 55 wherein the support casing includes at least one horizontally disposed member that contacts at least one of an upper and lower surface of the tissue scaffold wafer and wherein the support casing includes at least one columnar extension extending from the horizontally disposed member along a side perimeter of the tissue scaffold wafer. 57. The device of claim 56 wherein the horizontally disposed member of the support casing includes at least one ring that contacts an outer perimeter of at least one of an upper and lower surface of the tissue scaffold wafer. 58. The device of claim 56 wherein the horizontally disposed member includes a bracket member. 59. The device of claim 56 wherein the horizontally disposed member includes a pad member. 60. The device of claim 56 wherein the horizontally disposed member includes a brace member. 61. The device of claim 55 wherein the support casing includes a plurality of the columnar extensions of the support material. 62. The device of claim 55 wherein the support casing is biodegradable in a mouth of an animal.
Okuzumi Yuzi (Belle Mead NJ) Mellon A. Darline (Bridgewater NJ) Wasserman David (Springfield NJ), Addition copolymers of lactide and glycolide and method of preparation.
Delcommune Luc (Monfalcone ITX) Ghyselinck Philippe (Braine-L\Alleud BEX), Article made of lactic acid polymer capable of being employed particularly as a biodegradable prosthesis and process for.
Calhoun Jason H. (Galveston TX) Mader Jon T. (Galveston TX), Biodegradable antibiotic implants and methods of their use in treating and preventing infections.
Tuan Rocky S. (Chester Springs PA) Lin Sheldon S. (Philadelphia PA), Biodegradable drug delivery system for the prevention and treatment of osteomyelitis.
Dunn Richard L. (451 Boardwalk Dr. RLD ; Apt. 501 Fort Collins CO 80526) English James P. (2500 Melinda Cir. Birmingham AL 35214) Cowsar Donald R. (4657 Round Forest Dr. Birmingham AL 35213) Vanderbi, Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David D. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Dunn Richard L. (Fort Collins CO) English James P. (Birmingham AL) Cowsar Donald R. (Birmingham AL) Vanderbilt David P. (Birmingham AL), Biodegradable in-situ forming implants and methods of producing the same.
Silver Frederick A. (Long Valley NJ) Berg Richard A. (Lambertville NJ) Birk David E. (Somerset NJ) Weadock Kevin (Piscataway NJ) Whyne Conrad (Somerset NJ), Biodegradable matrix and methods for producing same.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Southard George L. (Fort Collins CO) Rogers Jack A. (Fort Collins CO), Biodegradable system for regenerating the periodontium.
Kaplan, Donald S.; Hermes, Matthew; Muth, Ross R.; Kennedy, John, Blends of glycolide and/or lactide polymers and caprolactone and/or trimethylene carbonate polymers and absorbable surgical devices made therefrom.
Jefferies Steven R. (5802 Leith Walk Baltimore MD 21239) Gutmann James L. (10112 Daventry Dr. Cockeysville MD 21030) Heatfield Barry M. (33 Penny La. Baltimore MD 21209), Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Wozney John M. (Hudson MA) Wang Elizabeth A. (Carlisle MA) Rosen Vicki A. (Brookline MA) Celeste Anthony J. (Hudson MA), DNA sequences encoding BMP-6 proteins.
Muchow David C. (Transit Township ; Sibley County MN) Sirvio Larry M. (Cottage Grove MN), Device and method for extended delivery of pharmacologically active agents to the ear.
Dunn Richard L. (Fort Collins CO) Tipton Arthur J. (Fort Collins CO) Harkrader Ronald J. (Louisville CO) Rogers Jack A. (Fort Collins CO), Intragingival delivery systems for treatment of periodontal disease.
Rutherford Robert B. (Farmington CT), Issue repair and regeneration through the use of platelet derived growth factor (PDGF) in combination with dexamethasone.
Trml Pertti (Reikonkatu 7 C 7 SF-33730 Tampere FIX) Vainionp Seppo (Orapihlajatie 21-27 B 12 SF-00320 Helsinki FIX) Rokkanen Pentti (Marjaniemenranta 29 SF-00930 Helsinki FIX) Helevirta Pertti (Ojava, Layered surgical biocomposite material.
Tang Reginald T. (Warren NJ) Mares Frank (Whippany NJ) Boyle ; Jr. William J. (Parsippany NJ) Chiu Tin-Ho (Millburn NJ) Patel Kundanbhai M. (Landing NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
Wahlig Helmut (Darmstadt DEX) Dingeldain Elvira (Dreieich DEX) Braun Dietrich (Darmstadt-Arheilgen DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Peyman Gholam A. (123 Walnut St. New Orleans LA 70118), Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye.
March Keith L. (Carmel IN) Hathaway David R. (Indianapolis IN) Wilensky Robert L. (Indianapolis IN), Method for delivery of smooth muscle cell inhibitors.
Hermes Matthew E. (Easton CT) Muth Ross R. (Brookfield CT), Method for improving the storage stability of a polymeric article susceptible to hydrolytic degradation and resulting ar.
Rutherford Robert B. (Farmington CT) Charette Marc F. (Needham MA), Method for promoting tissue repair and regeneration using PDGF and glucocorticoids.
Tice Thomas R. (Birmingham AL) Dillon Deborah L. (Helena AL) Mason David W. (Birmingham AL) McRae-McFarlane Amanda (Vastra Frolunda SEX) Dahlstrom Annica B. (Askin SEX), Method for stimulating nerve fiber growth.
Brizzolara Nancy S. (Congers NY) Lanzilotti Michael G. (Pearl River NY) Lawter James R. (Goshen NY), Method for the treatment of periodontal disease by sustained delivery of a therapeutic agent to the periodontal pocket,.
Tung Ming S. (15233 Falconbridge Ter. Gaithersburg MD 20878), Methods and compositions for mineralizing and/or fluoridating calcified tissues with amorphous strontium compounds.
Vert Michel (Deville-les-Rouen FRX) Chabot Francois (Rouen FRX) Leray Jean (Sevres FRX) Christel Pascal (Paris FRX), New prosthesis parts, their preparation and their application.
Mathiowitz Edith (Brookline MA) Langer Robert S. (Somerville MA) Warshawsky Abraham (Rehovot MA ILX) Edelman Elazar (Brookline MA), Polymer composite for controlled release or membrane formation.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Kaplan Donald S. (Weston CT) Hermes Matthew E. (Norwalk CT) Muth Ross R. (Brookfield CT) Kennedy John J. (Stratford CT), Process for making a surgical device using two-phase compositions.
Kaplan Donald S. (Weston CT) Hermes Matthew E. (Norwalk CT) Muth Ross R. (Brookfield CT) Kennedy John J. (Stratford CT), Process of making an absorbable surgical device.
Jamiolkowski Dennis D. (Long Valley NJ) Gaterud Mark T. (Annandale NJ) Newman ; Jr. Hugh D. (Chester NJ) Shalaby Shalaby W. (Lebanon NJ), Surgical fastener made from glycolide-rich polymer blends.
Smith Carl R. (Bloomingdale NJ) Gaterud Mark T. (Annandale NJ) Jamiolkowski Dennis D. (Long Valley NJ) Newman ; Jr. Hugh D. (Chester NJ) Shalaby Shalaby W. (Lebanon NJ), Surgical fastener made from glycolide-rich polymer blends.
Orsolini Piero (Martigny) Mauvernay Rolland-Yves (Lausanne) Deghenghi Romano (Lausanne CHX), Sustained and controlled release of water insoluble polypeptides.
Kaplan Donald S. (Weston CT) Hermes Matthew E. (Norwalk CT) Muth Ross R. (Brookfield CT) Kennedy John J. (Stratford CT), Two-phase compositions for absorbable surgical devices.
Smith, R. Lane; Tarrant, Laurence J. B.; Kusanagi, Akihiko; Claesson, Hans P. I., Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof.
Claesson, Hans P. i.; Tarrant, Laurence J. B.; Smith, R. Lane; Shortkroff, Sonya, Double-structured tissue implant and a method for preparation and use thereof.
Claesson, Hans Peter Ingemar; Tarrant, Laurence J. B.; Smith, Robert Lane; Shortkroff, Sonya, Double-structured tissue implant and a method for preparation and use thereof.
Claesson, Hans Peter Ingemar; Tarrant, Laurence J. B.; Smith, Robert Lane; Shortkroff, Sonya, Double-structured tissue implant and a method for preparation and use thereof.
Wang, Shanfeng; Lu, Lichun; Yaszemski, Michael J., Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof.
Shortkroff, Sonya; Khoury, Joseph; Tarrant, Laurence J. B.; Claesson, Hans P. I.; Smith, Robert Lane, Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant.
Shortkroff, Sonya; Tarrant, Laurence J. B.; Roos, Eric J.; Smith, Robert Lane; Claesson, Hans P. I., Method for use of a double-structured tissue implant for treatment of tissue defects.
Shortkroff, Sonya; Tarrant, Laurence J. B.; Roos, Eric J.; Smith, Robert Lane; Claesson, Hans P. I., Method for use of a double-structured tissue implant for treatment of tissue defects.
Leonard, Edward F.; West, Alan C.; Shapley, Nina C.; Tang, Zhongliang, Methods of blood-based therapies having a microfluidic membraneless exchange device.
Leonard, Edward F.; West, Alan C.; Shaplely, Nina C.; Tang, Zhongliang, Systems and methods of blood-based therapies having a microfluidic membraneless exchange device.
Leonard, Edward F.; West, Alan C.; Shapley, Nina C.; Tang, Zhongliang, Systems and methods of blood-based therapies having a microfluidic membraneless exchange device.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian P.; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian Paul; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian Paul; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian Paul; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian Paul; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
Leonard, Edward F.; West, Alan C.; Aucoin, Christian Paul; Nanne, Edgar E., Systems and methods of microfluidic membraneless exchange using filtration of extraction outlet streams.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.